Will Vertex Pharmaceuticals Q2 results bring positive surprise?
Zerbor/iStock via Getty Images

Vertex Pharmaceuticals (NASDAQ:VRTX) is scheduled to announce Q2 earnings results on Thursday, August 4th, after market close.
The consensus EPS Estimate is $3.50 (+12.5% Y/Y) and the consensus Revenue Estimate is $2.13B (+19.0% Y/Y).
Over the last 2 years, VRTX has beaten EPS estimates 75% of the time and has beaten revenue estimates 100% of the time.
Over the last 3 months, EPS estimates have seen 3 upward revisions and 13 downward. Revenue estimates have seen 9 upward revisions and 3 downward.
The company's stock dipped -4.67% on May 6, the day after it reported its Q1 results post market May 5. The cystic fibrosis drugmaker's revenue beat analysts' estimates but non-GAAP EPS missed expectations. Trikafta sales in Q1 were ~$1.8B.

In July, VRTX was among UBS' highest conviction stock picks for the rest of 2022. Meanwhile, Cantor Fitzgerald initiated Vertex with an overweight rating on growth prospects.
M&A and Pipeline: In an effort to to bolster its diabetes pipeline, Vertex is acquiring ViaCyte. The company also entered a gene editing partnership with Verve Therapeutics worth up to $466M for liver disease.
In addition, Vertex is buying protease drugs from Catalyst Bio for $60M in cash. The company is also expanding its presence in Boston area with a new cell/gene therapy facility.
In July, the company said the FDA lifted a clinical hold on its trial of VX-880, a stem cell-based therapy for certain patients with type 1 diabetes.